Citius Pharmaceuticals, Inc. Research and Development Expense
Citius Pharmaceuticals, Inc. (CTXR) reported Research and Development Expense of $1.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Citius Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-06-30 was $1.05M, a 35.00% decline year-over-year.
- Citius Pharmaceuticals, Inc. research and development expense for the quarter ending 2026-03-31 was $1.63M, a 56.63% decline year-over-year.
- Citius Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-12-31 was $1.60M, a 24.79% decline year-over-year.
- Citius Pharmaceuticals, Inc. research and development expense for the quarter ending 2025-09-30 was $1.64M, a 43.68% decline year-over-year.
- Citius Pharmaceuticals, Inc. research and development expense for fiscal 2025 was $9.16M, a 23.10% decline from fiscal 2024.
- Citius Pharmaceuticals, Inc. research and development expense for fiscal 2024 was $11.91M, a 19.66% decline from fiscal 2023.
- Citius Pharmaceuticals, Inc. research and development expense for fiscal 2023 was $14.82M, a 16.06% decline from fiscal 2022.
- Citius Pharmaceuticals, Inc. research and development expense for fiscal 2022 was $17.66M, a 44.24% increase from fiscal 2021.
| Period end | Research and Development Expense | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.05M 10-Q · filed 2026-08-14 | $2.69M derived: sum of 2 quarters · filed 2026-08-14 | $4.29M 10-Q · filed 2026-08-14 | $5.93M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $1.63M 10-Q · filed 2026-05-15 | $3.23M 10-Q · filed 2026-05-15 | $4.87M derived: sum of 3 quarters · filed 2026-05-15 | $6.50M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $1.60M 10-Q · filed 2026-02-13 | $3.24M derived: sum of 2 quarters · filed 2026-02-13 | $4.86M derived: sum of 3 quarters · filed 2026-08-14 | $8.63M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-09-30 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $3.26M derived: sum of 2 quarters · filed 2026-08-14 | $7.03M derived: sum of 3 quarters · filed 2026-08-14 | $9.16M 10-K · filed 2025-12-23 | |
| 2025-06-30 | $1.62M 10-Q · filed 2026-08-14 | $5.39M derived: sum of 2 quarters · filed 2026-08-14 | $7.51M 10-Q · filed 2026-08-14 | $10.43M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $3.77M 10-Q · filed 2026-05-15 | $5.89M 10-Q · filed 2026-05-15 | $8.81M derived: sum of 3 quarters · filed 2026-05-15 | $11.57M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $2.13M 10-Q · filed 2026-02-13 | $5.04M derived: sum of 2 quarters · filed 2026-02-13 | $7.81M derived: sum of 3 quarters · filed 2026-02-13 | $11.41M derived: sum of 4 quarters · filed 2026-02-13 | |
| 2024-09-30 | $2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-23 | $5.68M derived: sum of 2 quarters · filed 2025-12-23 | $9.28M derived: sum of 3 quarters · filed 2025-12-23 | $11.91M 10-K · filed 2025-12-23 | |
| 2024-08-31 | $33.40M 10-Q · filed 2025-08-12 | ||||
| 2024-06-30 | $2.76M 10-Q · filed 2025-08-12 | $6.37M derived: sum of 2 quarters · filed 2025-08-12 | $8.99M 10-Q · filed 2025-08-12 | $11.87M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $3.61M 10-Q · filed 2025-05-14 | $6.23M 10-Q · filed 2025-05-14 | $9.11M derived: sum of 3 quarters · filed 2025-05-14 | $12.88M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $2.62M 10-Q · filed 2025-02-14 | $5.50M derived: sum of 2 quarters · filed 2025-02-14 | $9.27M derived: sum of 3 quarters · filed 2025-02-14 | $14.00M derived: sum of 4 quarters · filed 2025-02-14 | |
| 2023-09-30 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-27 | $6.65M derived: sum of 2 quarters · filed 2024-12-27 | $11.37M derived: sum of 3 quarters · filed 2024-12-27 | $14.82M 10-K · filed 2024-12-27 | |
| 2023-06-30 | $3.76M 10-Q · filed 2024-08-12 | $8.49M derived: sum of 2 quarters · filed 2024-08-12 | $11.94M 10-Q · filed 2024-08-12 | $15.79M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $4.73M 10-Q · filed 2024-05-14 | $8.17M 10-Q · filed 2024-05-14 | $12.03M derived: sum of 3 quarters · filed 2024-05-14 | $16.92M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $3.45M 10-Q · filed 2024-02-14 | $7.30M derived: sum of 2 quarters · filed 2024-02-14 | $12.19M derived: sum of 3 quarters · filed 2024-02-14 | $15.64M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2022-09-30 | $3.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-29 | $8.75M derived: sum of 2 quarters · filed 2023-12-29 | $12.20M derived: sum of 3 quarters · filed 2023-12-29 | $17.66M 10-K · filed 2023-12-29 | |
| 2022-06-30 | $4.89M 10-Q · filed 2023-08-14 | $8.34M derived: sum of 2 quarters · filed 2023-08-14 | $13.80M 10-Q · filed 2023-08-14 | $16.09M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $3.45M 10-Q · filed 2023-05-12 | $8.91M 10-Q · filed 2023-05-12 | $11.20M derived: sum of 3 quarters · filed 2023-05-12 | $13.41M derived: sum of 4 quarters · filed 2023-05-12 | |
| 2021-12-31 | $5.46M 10-Q · filed 2023-02-10 | $7.75M derived: sum of 2 quarters · filed 2023-02-10 | $9.96M derived: sum of 3 quarters · filed 2023-02-10 | $11.51M derived: sum of 4 quarters · filed 2023-02-10 | |
| 2021-09-30 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-22 | $4.50M derived: sum of 2 quarters · filed 2022-12-22 | $6.05M derived: sum of 3 quarters · filed 2022-12-22 | $12.24M 10-K · filed 2022-12-22 | |
| 2021-06-30 | $2.20M 10-Q · filed 2022-08-11 | $3.76M derived: sum of 2 quarters · filed 2022-08-11 | $9.95M 10-Q · filed 2022-08-11 | $11.43M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $1.55M 10-Q · filed 2022-05-12 | $7.74M 10-Q · filed 2022-05-12 | $9.23M derived: sum of 3 quarters · filed 2022-05-12 | $11.87M derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $6.19M 10-Q · filed 2022-02-10 | $7.68M derived: sum of 2 quarters · filed 2022-02-10 | $10.32M derived: sum of 3 quarters · filed 2022-02-10 | $12.34M derived: sum of 4 quarters · filed 2022-02-10 | |
| 2020-09-30 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-15 | $4.13M derived: sum of 2 quarters · filed 2021-12-15 | $6.15M derived: sum of 3 quarters · filed 2021-12-15 | $8.81M 10-K · filed 2021-12-15 | |
| 2020-06-30 | $2.64M 10-Q · filed 2021-08-12 | $4.66M derived: sum of 2 quarters · filed 2021-08-12 | $7.32M 10-Q · filed 2021-08-12 | $9.34M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $2.02M 10-Q · filed 2021-05-13 | $4.68M 10-Q · filed 2021-05-13 | $6.70M derived: sum of 3 quarters · filed 2021-05-13 | $9.46M derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $2.66M 10-Q · filed 2021-02-11 | $4.68M derived: sum of 2 quarters · filed 2021-02-11 | $7.45M derived: sum of 3 quarters · filed 2021-02-11 | $9.15M derived: sum of 4 quarters · filed 2021-02-11 | |
| 2019-09-30 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-16 | $4.78M derived: sum of 2 quarters · filed 2020-12-16 | $6.48M derived: sum of 3 quarters · filed 2020-12-16 | $8.60M 10-K · filed 2020-12-16 | |
| 2019-06-30 | $2.77M 10-Q · filed 2020-08-14 | $4.47M derived: sum of 2 quarters · filed 2020-08-14 | $6.58M 10-Q · filed 2020-08-14 | $8.32M derived: sum of 4 quarters · filed 2020-08-14 | |
| 2019-03-31 | $1.70M 10-Q · filed 2020-05-14 | $3.81M 10-Q · filed 2020-05-14 | $5.55M derived: sum of 3 quarters · filed 2020-05-14 | $6.33M derived: sum of 4 quarters · filed 2020-05-14 | |
| 2018-12-31 | $2.11M 10-Q · filed 2020-02-13 | $3.85M derived: sum of 2 quarters · filed 2020-02-13 | $4.63M derived: sum of 3 quarters · filed 2020-02-13 | $8.07M derived: sum of 4 quarters · filed 2020-02-13 | |
| 2018-09-30 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-16 | $2.52M derived: sum of 2 quarters · filed 2019-12-16 | $5.96M derived: sum of 3 quarters · filed 2019-12-16 | $6.56M 10-K · filed 2019-12-16 | |
| 2018-06-30 | $778.86K 10-Q · filed 2018-08-14 | $4.22M derived: sum of 2 quarters · filed 2019-08-14 | $4.83M 10-Q · filed 2019-08-14 | $5.30M derived: sum of 4 quarters · filed 2019-12-16 | |
| 2018-03-31 | $3.44M 10-Q · filed 2019-05-15 | $4.05M 10-Q · filed 2019-05-15 | $4.52M derived: sum of 3 quarters · filed 2019-12-16 | $4.71M derived: sum of 4 quarters · filed 2019-12-16 | |
| 2017-12-31 | $606.52K 10-Q · filed 2019-02-14 | $1.08M derived: sum of 2 quarters · filed 2019-12-16 | $1.27M derived: sum of 3 quarters · filed 2019-12-16 | $2.13M derived: sum of 4 quarters · filed 2019-12-16 | |
| 2017-09-30 | $474.53K derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-16 | $665.18K derived: sum of 2 quarters · filed 2019-12-16 | $1.53M derived: sum of 3 quarters · filed 2019-12-16 | $2.94M 10-K · filed 2019-12-16 | |
| 2017-06-30 | $190.65K 10-Q · filed 2018-08-14 | $1.05M derived: sum of 2 quarters · filed 2018-08-14 | $2.46M 10-Q · filed 2018-08-14 | $4.38M derived: sum of 4 quarters · filed 2018-12-11 | |
| 2017-03-31 | $859.91K 10-Q · filed 2018-05-11 | $2.27M 10-Q · filed 2018-05-11 | $4.19M derived: sum of 3 quarters · filed 2018-12-11 | $4.58M derived: sum of 4 quarters · filed 2018-12-11 | |
| 2016-12-31 | $1.41M 10-Q · filed 2018-02-14 | $3.33M derived: sum of 2 quarters · filed 2018-12-11 | $3.72M derived: sum of 3 quarters · filed 2018-12-11 | $3.52M derived: sum of 4 quarters · filed 2018-12-11 | |
| 2016-09-30 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-11 | $2.30M derived: sum of 2 quarters · filed 2018-12-11 | $2.10M derived: sum of 3 quarters · filed 2018-12-11 | $2.93M 10-K · filed 2018-12-11 | |
| 2016-06-30 | $381.12K 10-Q · filed 2017-08-14 | $180.82K derived: sum of 2 quarters · filed 2017-08-14 | $1.01M 10-Q · filed 2017-08-14 | $1.63M derived: sum of 4 quarters · filed 2017-12-13 | |
| 2016-03-31 | -$200.30K 10-Q · filed 2017-05-15 | $628.86K 10-Q · filed 2017-05-15 | $1.25M derived: sum of 3 quarters · filed 2017-12-13 | $1.67M derived: sum of 4 quarters · filed 2017-12-13 | |
| 2015-12-31 | $829.16K 10-Q · filed 2017-02-14 | $1.45M derived: sum of 2 quarters · filed 2017-12-13 | $1.87M derived: sum of 3 quarters · filed 2017-12-13 | $2.15M derived: sum of 4 quarters · filed 2017-12-13 | |
| 2015-09-30 | $622.15K derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-13 | $1.04M derived: sum of 2 quarters · filed 2017-12-13 | $1.32M derived: sum of 3 quarters · filed 2017-12-13 | $1.80M 10-K · filed 2017-12-13 | |
| 2015-06-30 | $415.53K 10-Q · filed 2016-08-15 | $697.77K derived: sum of 2 quarters · filed 2016-08-15 | $1.17M 10-Q · filed 2016-08-15 | $738.07K derived: sum of 4 quarters · filed 2016-12-23 | |
| 2015-03-31 | $282.24K 10-Q · filed 2016-05-20 | $759.36K 10-Q · filed 2016-05-20 | $322.54K derived: sum of 3 quarters · filed 2016-12-23 | $322.54K derived: sum of 4 quarters · filed 2016-12-23 | |
| 2014-12-31 | $477.12K 10-Q · filed 2016-02-12 | $40.30K derived: sum of 2 quarters · filed 2016-12-23 | $40.30K derived: sum of 3 quarters · filed 2016-12-23 | $40.30K derived: sum of 4 quarters · filed 2016-12-23 | |
| 2014-09-30 | -$436.82K derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-23 | -$436.82K derived: sum of 2 quarters · filed 2016-12-23 | $574.00 10-K · filed 2015-12-14 | $574.00 10-K · filed 2016-12-23 | |
| 2014-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-08-13 | $0.00 derived: sum of 2 quarters · filed 2015-08-13 | $437.40K 10-Q · filed 2015-08-13 | ||
| 2014-03-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-05-13 | $437.40K 10-Q · filed 2015-05-13 | |||
| 2013-12-31 | $437.40K 10-Q · filed 2015-02-17 | $492.14K 10-K · filed 2015-12-14 | |||
| 2012-12-31 | $705.81K 10-KT · filed 2014-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |